These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. [Clinical polymorphism of amyotrophic lateral sclerosis]. Kovrazhkina EA; Razinskaya OD; Gubsky LV Zh Nevrol Psikhiatr Im S S Korsakova; 2017; 117(8):4-10. PubMed ID: 28884711 [TBL] [Abstract][Full Text] [Related]
23. Excitotoxicity and amyotrophic lateral sclerosis. Van Damme P; Dewil M; Robberecht W; Van Den Bosch L Neurodegener Dis; 2005; 2(3-4):147-59. PubMed ID: 16909020 [TBL] [Abstract][Full Text] [Related]
24. Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model. Fellner A; Barhum Y; Angel A; Perets N; Steiner I; Offen D; Lev N Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28763002 [TBL] [Abstract][Full Text] [Related]
25. Three soccer playing friends with simultaneous amyotrophic lateral sclerosis. Wicks P; Ganesalingham J; Collin C; Prevett M; Leigh NP; Al-Chalabi A Amyotroph Lateral Scler; 2007 Jun; 8(3):177-9. PubMed ID: 17538780 [TBL] [Abstract][Full Text] [Related]
26. Molecular insights and therapeutic targets in amyotrophic lateral sclerosis. Tripathi VB; Al-Chalabi A CNS Neurol Disord Drug Targets; 2008 Feb; 7(1):11-9. PubMed ID: 18289027 [TBL] [Abstract][Full Text] [Related]
27. Identification and outcomes of clinical phenotypes in amyotrophic lateral sclerosis/motor neuron disease: Australian National Motor Neuron Disease observational cohort. Talman P; Duong T; Vucic S; Mathers S; Venkatesh S; Henderson R; Rowe D; Schultz D; Edis R; Needham M; Macdonnell R; McCombe P; Birks C; Kiernan M BMJ Open; 2016 Sep; 6(9):e012054. PubMed ID: 27694488 [TBL] [Abstract][Full Text] [Related]
28. Epigenetic Mechanisms of Gene Regulation in Amyotrophic Lateral Sclerosis. Jimenez-Pacheco A; Franco JM; Lopez S; Gomez-Zumaquero JM; Magdalena Leal-Lasarte M; Caballero-Hernandez DE; Cejudo-Guillén M; Pozo D Adv Exp Med Biol; 2017; 978():255-275. PubMed ID: 28523551 [TBL] [Abstract][Full Text] [Related]
29. Clinical Spectrum of Amyotrophic Lateral Sclerosis (ALS). Grad LI; Rouleau GA; Ravits J; Cashman NR Cold Spring Harb Perspect Med; 2017 Aug; 7(8):. PubMed ID: 28003278 [TBL] [Abstract][Full Text] [Related]
30. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? Bellingham MC CNS Neurosci Ther; 2011 Feb; 17(1):4-31. PubMed ID: 20236142 [TBL] [Abstract][Full Text] [Related]
31. Riluzole does not have an acute effect on motor thresholds and the intracortical excitability in amyotrophic lateral sclerosis. Sommer M; Tergau F; Wischer S; Reimers CD; Beuche W; Paulus W J Neurol; 1999 Nov; 246 Suppl 3():III22-6. PubMed ID: 10631657 [TBL] [Abstract][Full Text] [Related]
32. Clinical features and prognosis of amyotrophic lateral sclerosis in Africa: the TROPALS study. Luna J; Diagana M; Ait Aissa L; Tazir M; Ali Pacha L; Kacem I; Gouider R; Henning F; Basse A; Cisse O; Balogou AAK; Kombate D; Agbetou M; Houinato D; Millogo A; Agba T; Belo M; Penoty M; Raymondeau-Moustafa M; Hamidou B; Couratier P; Preux PM; Marin B; J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):20-29. PubMed ID: 30242088 [TBL] [Abstract][Full Text] [Related]
33. Clinical features that distinguish PLS, upper motor neuron-dominant ALS, and typical ALS. Gordon PH; Cheng B; Katz IB; Mitsumoto H; Rowland LP Neurology; 2009 Jun; 72(22):1948-52. PubMed ID: 19487653 [TBL] [Abstract][Full Text] [Related]
34. Emerging Drugs for the Treatment of Amyotrophic Lateral Sclerosis: A Focus on Recent Phase 2 Trials. Barp A; Gerardi F; Lizio A; Sansone VA; Lunetta C Expert Opin Emerg Drugs; 2020 Jun; 25(2):145-164. PubMed ID: 32456491 [TBL] [Abstract][Full Text] [Related]
35. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. Chiò A; Calvo A; Moglia C; Mazzini L; Mora G; J Neurol Neurosurg Psychiatry; 2011 Jul; 82(7):740-6. PubMed ID: 21402743 [TBL] [Abstract][Full Text] [Related]
37. The Role of Iron in Amyotrophic Lateral Sclerosis. Bu XL; Xiang Y; Guo Y Adv Exp Med Biol; 2019; 1173():145-152. PubMed ID: 31456209 [TBL] [Abstract][Full Text] [Related]
38. Advances in the Development of Disease-Modifying Treatments for Amyotrophic Lateral Sclerosis. Moujalled D; White AR CNS Drugs; 2016 Mar; 30(3):227-43. PubMed ID: 26895253 [TBL] [Abstract][Full Text] [Related]
39. Pathophysiology and Diagnosis of ALS: Insights from Advances in Neurophysiological Techniques. van den Bos MAJ; Geevasinga N; Higashihara M; Menon P; Vucic S Int J Mol Sci; 2019 Jun; 20(11):. PubMed ID: 31185581 [TBL] [Abstract][Full Text] [Related]
40. Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial. Kim S; Kim JK; Son MJ; Kim D; Song B; Son I; Kang HW; Lee J; Kim S Trials; 2018 Apr; 19(1):225. PubMed ID: 29653550 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]